- $1.39bn
- $1.48bn
- $53.04m
AnaptysBio climbs on plans to split into two public companies
AnaptysBio's Q4 collaboration revenue more than doubled; details spin-off plan
Brief: AnaptysBio Q4 Net Income USD 49.614 Million
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty
Brief: Anaptys Files Motion To Dismiss Tesaro'S Claim Of Anticipatory Breach Of Contract In Ongoing Litigation
Brief: Vanda Announces Submission Of Biologics License Application To The FDA For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis
Brief: AnaptysBio's Complaint Against Tesaro For Breaching Agreement Was Publicly Filed On Nov 26 - SEC Filing
U.S. STOCKS ON THE MOVE-IES Holding, Eli Lilly, Alphabet
AnaptysBio shares tumble after legal fight with GSK over cancer drug license (updated)
U.S. STOCKS ON THE MOVE-Intuit, IES Holding, Workday
AnaptysBio tumbles after latest legal battle over cancer drug
AnaptysBio shares tumble after legal fight with GSK over cancer drug license
Esperion rises as partner launches cholesterol drug in Japan
U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare
U.S. STOCKS ON THE MOVE-Eli Lilly, Fossil, Papa John's
AnaptysBio falls after ulcerative colitis drug fails in mid-stage trial
AnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli sales
Brief: AnaptysBio Q3 Net Income USD 15.113 Million
Brief: Anaptys Announces New Positive Phase 2B Trial Results For Rosnilimab In Rheumatoid Arthritis